Amyl Therapeutics
Personnes
7
Sites
1
Publications
13
Profil de l'entreprise
Date de création
26 novembre 2020
Dernier bilan (année)
2024
Forme juridique
Besloten Vennootschap
Type d'entreprise
Rechtspersoon
Activité
72101 - Speur- en ontwikkelingswerk op biotechnologisch gebied
Âge de l'entreprise
6 ans
Coordonnées
Unlock direct contact points, registry address detail, and website links for Amyl Therapeutics.
Unlock Contact Details
Reveal email, phone, website, and full registry contact information.
Create Free AccountHistorique Financier
| KPI | 2024 | 2023 | 2022 |
|---|---|---|---|
| Chiffre d'affaires | - | - | - |
| Marge brute | -872 434 € (-29.4%) | -674 399 € (+19.8%) | -840 592 € (+3.9%) |
| Bénéfice | -2 436 601 € (-42.5%) | -1 709 641 € (-20.8%) | -1 415 300 € (-41.6%) |
| EBITDA | -12 586 € (-105.4%) | 231 272 € (+218.5%) | -195 232 € (+70.9%) |
| Capitaux propres | 5 562 413 € (-30.5%) | 7 999 014 € (+28.8%) | 6 208 656 € (-18.6%) |
| Dettes | 2 682 460 € (+178.0%) | 964 985 € (+95.4%) | 493 938 € (-54.9%) |
| Total des actifs | 8 385 696 € (-6.5%) | 8 963 999 € (+33.7%) | 6 702 593 € (-23.2%) |
| Trésorerie | 2 283 118 € (-26.1%) | 3 089 277 € (+106.7%) | 1 494 636 € (-58.7%) |
| ETP (FTE) | 4,6 (0.0%) | 4,6 (+100.0%) | 2,3 (+228.6%) |
Unlock Full History
Create a free account to access up to 10 years of historical financial data for Amyl Therapeutics.
Create Free AccountSanté Financière
Ratio-level insight derived from the latest company and balance sheet data.
Current Ratio
5,3x
(+30.0%)
Quick Ratio
5,3x
(+30.0%)
Solvency
66,3%
(-25.7%)
Debt / Equity
0,5x
Unlock Advanced Metrics
Access the full ratio deck, benchmarking signals, and deeper profitability diagnostics.
Create Free AccountImplantations & Empreinte
Establishment
AdresseBoulevard de Patience et Beaujonc 3, 4000 Luik, Belgium
Réseau d'entités
First-level relations linked directly to Amyl Therapeutics. Unlock second-level relations for deeper graph exploration.
Amyl Therapeutics
Actif
- NOSHAQ
Incoming link
Administrator Legal - NOSHAQ PARTNERS
Incoming link
Administrator Legal - VACCIBIO CONSULTING
Incoming link
Administrator Legal -
Kenneth BUCKFIRE
Incoming link
Administrator Natural -
Valérie CALENDA
Incoming link
Administrator Natural - NOSHAQ
Outgoing link
Participating Interest - VACCIBIO CONSULTING
Outgoing link
Participating Interest - 6K venture capital
Incoming link
Shareholder Entity - NOSHAQ
Incoming link
Shareholder Entity - VACCIBIO CONSULTING
Incoming link
Shareholder Entity -
Evren Uçok
Incoming link
Shareholder Individual -
Kenneth BUCKFIRE
Incoming link
Shareholder Individual -
Amel TOUNSI
Incoming link
Administrator Legal Representative -
GROS FLORENT
Incoming link
Administrator Legal Representative -
Hélène SABATEL
Incoming link
Administrator Legal Representative -
Pierre Vandepapeliere
Incoming link
Administrator Legal Representative
Unlock Second-Level Relations
Expand beyond direct links to see second-level entities, people, and cross-company paths.
Free Sign UpPublications au Moniteur Belge
Direction & Personnes Clés
Unlock linked people, governance roles, and enriched demographic signals associated with Amyl Therapeutics.
Management Profiles
Unlock directors, managers, role history, plus inferred gender and age where available.
Create Free Account